newsfilter
← Latest News
GlobeNewswire·

Longeveron Announces Private Placement of up to $30 Million

$15 million upfront with a milestone-driven potential additional $15 million related to the Company's anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market under Nasdaq rules